Emami targets growth via buyback and D2C brands

has announced an open-market share buyback worth ₹282 crore at ₹475 per share, offering capital distribution support to shareholders as the stock has fallen over 30% in the past year. The company is balancing structural challenges in its core business with aggressive growth in its strategic portfolio. Input cost inflation, weak rural demand, and West Asia supply chain disruptions led to Q1FY27 EBITDA margins dropping to 21.8% from 23.7% year-on-year. In response, management is relying on its direct-to-consumer (D2C) and emerging brand investments, which grew 61% like-for-like to generate ₹160 crore in Q1FY27. Emami projects these strategic bets—including The Man Company, Brillare, and Axiom Ayurveda—to contribute 25% of consolidated turnover by FY30, up from 6% currently. While the market views the ₹282 crore buyback as a positive signal, the headline misses the core execution risk: turning rapid D2C top-line expansion into bottom-line profit. Strategic investments currently operate around EBITDA breakeven. However, losses are projected to narrow to -3% to -4% in FY27, with long-term targets of over 8% EBITDA margin. At 22x FY28 earnings, the valuation looks reasonable, but stock recovery hinges entirely on margin expansion in D2C subsidiaries and a rebound in international operations. Investors should monitor D2C EBITDA margin trends and international supply chain recovery in upcoming quarterly updates. Accumulate on operational execution. Disclosure: The content provided is for informational purposes only and should not be construed as investment advice. Please consult a qualified financial advisor before making any investment decisions.